nodes	percent_of_prediction	percent_of_DWPC	metapath
Pseudoephedrine—TNF—ankylosing spondylitis	0.794	1	CbGaD
Pseudoephedrine—IL2—synovial fluid—ankylosing spondylitis	0.047	0.903	CbGeAlD
Pseudoephedrine—IL2—IL23-mediated signaling events—IL23R—ankylosing spondylitis	0.00727	0.0515	CbGpPWpGaD
Pseudoephedrine—TNF—Cellular roles of Anthrax toxin—ANTXR2—ankylosing spondylitis	0.0041	0.0291	CbGpPWpGaD
Pseudoephedrine—IL2—Inflammatory Response Pathway—TNFRSF1B—ankylosing spondylitis	0.00384	0.0272	CbGpPWpGaD
Pseudoephedrine—IL2—IL27-mediated signaling events—IL17A—ankylosing spondylitis	0.00384	0.0272	CbGpPWpGaD
Pseudoephedrine—NFATC1—tendon—ankylosing spondylitis	0.00382	0.0734	CbGeAlD
Pseudoephedrine—IL2—IL27-mediated signaling events—IL12B—ankylosing spondylitis	0.00357	0.0253	CbGpPWpGaD
Pseudoephedrine—IL2—Cytokines and Inflammatory Response—IL12B—ankylosing spondylitis	0.00346	0.0245	CbGpPWpGaD
Pseudoephedrine—IL2—IL23-mediated signaling events—IL17A—ankylosing spondylitis	0.00289	0.0205	CbGpPWpGaD
Pseudoephedrine—NFATC1—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.00283	0.02	CbGpPWpGaD
Pseudoephedrine—TNF—IL23-mediated signaling events—IL23R—ankylosing spondylitis	0.00271	0.0192	CbGpPWpGaD
Pseudoephedrine—IL2—IL23-mediated signaling events—IL12B—ankylosing spondylitis	0.00269	0.0191	CbGpPWpGaD
Pseudoephedrine—IL2—Cytokines and Inflammatory Response—IL1A—ankylosing spondylitis	0.00255	0.018	CbGpPWpGaD
Pseudoephedrine—IL2—Cytokines and Inflammatory Response—IL10—ankylosing spondylitis	0.00253	0.0179	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling by Interleukins—IL1R2—ankylosing spondylitis	0.00247	0.0175	CbGpPWpGaD
Pseudoephedrine—IL2—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.00239	0.0169	CbGpPWpGaD
Pseudoephedrine—IL2—Inflammatory Response Pathway—CD40LG—ankylosing spondylitis	0.00233	0.0165	CbGpPWpGaD
Pseudoephedrine—IL2—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.00226	0.016	CbGpPWpGaD
Pseudoephedrine—NFATC1—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.00205	0.0145	CbGpPWpGaD
Pseudoephedrine—NFATC1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.00183	0.013	CbGpPWpGaD
Pseudoephedrine—IL2—IL12-mediated signaling events—IL12B—ankylosing spondylitis	0.00183	0.013	CbGpPWpGaD
Pseudoephedrine—NFATC1—BCR signaling pathway—CD79A—ankylosing spondylitis	0.00177	0.0126	CbGpPWpGaD
Pseudoephedrine—IL2—Allograft Rejection—HLA-C—ankylosing spondylitis	0.00173	0.0122	CbGpPWpGaD
Pseudoephedrine—NFATC1—TCR Signaling Pathway—IL17A—ankylosing spondylitis	0.00168	0.0119	CbGpPWpGaD
Pseudoephedrine—IL2—Allograft Rejection—IL17A—ankylosing spondylitis	0.00158	0.0112	CbGpPWpGaD
Pseudoephedrine—IL2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.00155	0.011	CbGpPWpGaD
Pseudoephedrine—IL2—Allograft Rejection—IL12B—ankylosing spondylitis	0.00147	0.0104	CbGpPWpGaD
Pseudoephedrine—TNF—IL27-mediated signaling events—IL17A—ankylosing spondylitis	0.00143	0.0101	CbGpPWpGaD
Pseudoephedrine—NFATC1—AP-1 transcription factor network—IL10—ankylosing spondylitis	0.0014	0.0099	CbGpPWpGaD
Pseudoephedrine—TNF—IL27-mediated signaling events—IL12B—ankylosing spondylitis	0.00133	0.00941	CbGpPWpGaD
Pseudoephedrine—NFATC1—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.00129	0.00914	CbGpPWpGaD
Pseudoephedrine—TNF—Cytokines and Inflammatory Response—IL12B—ankylosing spondylitis	0.00129	0.00913	CbGpPWpGaD
Pseudoephedrine—NFATC1—AP-1 transcription factor network—HLA-A—ankylosing spondylitis	0.00123	0.00872	CbGpPWpGaD
Pseudoephedrine—IL2—AP-1 transcription factor network—IL10—ankylosing spondylitis	0.00118	0.00837	CbGpPWpGaD
Pseudoephedrine—IL2—IL12-mediated signaling events—HLA-A—ankylosing spondylitis	0.00118	0.00835	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling by Interleukins—IL1RN—ankylosing spondylitis	0.00117	0.00827	CbGpPWpGaD
Pseudoephedrine—IL2—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	0.00115	0.00816	CbGpPWpGaD
Pseudoephedrine—NFATC1—TCR Signaling Pathway—IL1A—ankylosing spondylitis	0.00115	0.00814	CbGpPWpGaD
Pseudoephedrine—TNF—TGF-beta Receptor Signaling—RUNX3—ankylosing spondylitis	0.0011	0.00776	CbGpPWpGaD
Pseudoephedrine—IL2—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.00109	0.00773	CbGpPWpGaD
Pseudoephedrine—IL2—Allograft Rejection—IL1A—ankylosing spondylitis	0.00108	0.00764	CbGpPWpGaD
Pseudoephedrine—TNF—IL23-mediated signaling events—IL17A—ankylosing spondylitis	0.00108	0.00763	CbGpPWpGaD
Pseudoephedrine—IL2—Allograft Rejection—IL10—ankylosing spondylitis	0.00107	0.0076	CbGpPWpGaD
Pseudoephedrine—IL2—Allograft Rejection—CD40LG—ankylosing spondylitis	0.00107	0.0076	CbGpPWpGaD
Pseudoephedrine—TNF—Overview of nanoparticle effects—CRP—ankylosing spondylitis	0.00105	0.00743	CbGpPWpGaD
Pseudoephedrine—IL2—AP-1 transcription factor network—HLA-A—ankylosing spondylitis	0.00104	0.00738	CbGpPWpGaD
Pseudoephedrine—IL2—Folate Metabolism—CRP—ankylosing spondylitis	0.00104	0.00738	CbGpPWpGaD
Pseudoephedrine—IL2—Allograft Rejection—HLA-B—ankylosing spondylitis	0.00102	0.00723	CbGpPWpGaD
Pseudoephedrine—TNF—TNF receptor signaling pathway —TNFRSF1B—ankylosing spondylitis	0.00102	0.00719	CbGpPWpGaD
Pseudoephedrine—TNF—IL23-mediated signaling events—IL12B—ankylosing spondylitis	0.001	0.00709	CbGpPWpGaD
Pseudoephedrine—IL2—IL27-mediated signaling events—TNF—ankylosing spondylitis	0.000993	0.00704	CbGpPWpGaD
Pseudoephedrine—IL2—Cytokines and Inflammatory Response—TNF—ankylosing spondylitis	0.000964	0.00683	CbGpPWpGaD
Pseudoephedrine—TNF—Cytokines and Inflammatory Response—IL1A—ankylosing spondylitis	0.000947	0.00671	CbGpPWpGaD
Pseudoephedrine—IL2—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000945	0.0067	CbGpPWpGaD
Pseudoephedrine—TNF—Cytokines and Inflammatory Response—IL10—ankylosing spondylitis	0.000942	0.00667	CbGpPWpGaD
Pseudoephedrine—TNF—Matrix Metalloproteinases—MMP3—ankylosing spondylitis	0.000921	0.00652	CbGpPWpGaD
Pseudoephedrine—TNF—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000841	0.00596	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling by Interleukins—IL1A—ankylosing spondylitis	0.00084	0.00595	CbGpPWpGaD
Pseudoephedrine—IL2—Spinal Cord Injury—IL1A—ankylosing spondylitis	0.000783	0.00554	CbGpPWpGaD
Pseudoephedrine—IL2—Corticotropin-releasing hormone—TLR4—ankylosing spondylitis	0.000765	0.00542	CbGpPWpGaD
Pseudoephedrine—IL2—IL23-mediated signaling events—TNF—ankylosing spondylitis	0.000749	0.00531	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—KIR3DL1—ankylosing spondylitis	0.000734	0.0052	CbGpPWpGaD
Pseudoephedrine—NFATC1—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000697	0.00494	CbGpPWpGaD
Pseudoephedrine—NFATC1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	0.000696	0.00493	CbGpPWpGaD
Pseudoephedrine—MAOA—tendon—ankylosing spondylitis	0.000686	0.0132	CbGeAlD
Pseudoephedrine—TNF—FAS pathway and Stress induction of HSP regulation—IL1A—ankylosing spondylitis	0.000665	0.00471	CbGpPWpGaD
Pseudoephedrine—NFATC1—Innate Immune System—CARD9—ankylosing spondylitis	0.000662	0.00469	CbGpPWpGaD
Pseudoephedrine—TNF—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.000645	0.00457	CbGpPWpGaD
Pseudoephedrine—TNF—Allograft Rejection—HLA-C—ankylosing spondylitis	0.000642	0.00455	CbGpPWpGaD
Pseudoephedrine—IL2—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	0.000629	0.00446	CbGpPWpGaD
Pseudoephedrine—IL2—Spinal Cord Injury—TLR4—ankylosing spondylitis	0.000627	0.00444	CbGpPWpGaD
Pseudoephedrine—TNF—Apoptosis—TNFRSF1B—ankylosing spondylitis	0.000627	0.00444	CbGpPWpGaD
Pseudoephedrine—IL2—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.000627	0.00444	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—KIR3DL1—ankylosing spondylitis	0.000621	0.0044	CbGpPWpGaD
Pseudoephedrine—IL2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	0.000589	0.00417	CbGpPWpGaD
Pseudoephedrine—TNF—Allograft Rejection—IL17A—ankylosing spondylitis	0.000587	0.00416	CbGpPWpGaD
Pseudoephedrine—TNF—TNF alpha Signaling Pathway—TNFRSF1B—ankylosing spondylitis	0.000583	0.00413	CbGpPWpGaD
Pseudoephedrine—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.000575	0.00408	CbGpPWpGaD
Pseudoephedrine—NFATC1—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	0.000557	0.00395	CbGpPWpGaD
Pseudoephedrine—TNF—Allograft Rejection—IL12B—ankylosing spondylitis	0.000546	0.00387	CbGpPWpGaD
Pseudoephedrine—IL2—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.000545	0.00386	CbGpPWpGaD
Pseudoephedrine—SLC6A4—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000543	0.00385	CbGpPWpGaD
Pseudoephedrine—ADRA2A—tendon—ankylosing spondylitis	0.000526	0.0101	CbGeAlD
Pseudoephedrine—NFATC1—Disease—ANTXR2—ankylosing spondylitis	0.000513	0.00364	CbGpPWpGaD
Pseudoephedrine—TNF—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	0.000476	0.00337	CbGpPWpGaD
Pseudoephedrine—IL2—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	0.000471	0.00334	CbGpPWpGaD
Pseudoephedrine—IL2—Folate Metabolism—TNF—ankylosing spondylitis	0.000471	0.00334	CbGpPWpGaD
Pseudoephedrine—TNF—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000469	0.00332	CbGpPWpGaD
Pseudoephedrine—MAOA—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000445	0.00315	CbGpPWpGaD
Pseudoephedrine—TNF—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	0.000445	0.00315	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—IL1R2—ankylosing spondylitis	0.000445	0.00315	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—ERAP1—ankylosing spondylitis	0.000421	0.00299	CbGpPWpGaD
Pseudoephedrine—NFATC1—Innate Immune System—HLA-C—ankylosing spondylitis	0.000416	0.00294	CbGpPWpGaD
Pseudoephedrine—IL2—Allograft Rejection—TNF—ankylosing spondylitis	0.000408	0.00289	CbGpPWpGaD
Pseudoephedrine—TNF—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000406	0.00288	CbGpPWpGaD
Pseudoephedrine—TNF—Allograft Rejection—IL1A—ankylosing spondylitis	0.000401	0.00284	CbGpPWpGaD
Pseudoephedrine—TNF—Allograft Rejection—IL10—ankylosing spondylitis	0.000399	0.00283	CbGpPWpGaD
Pseudoephedrine—TNF—Allograft Rejection—CD40LG—ankylosing spondylitis	0.000399	0.00283	CbGpPWpGaD
Pseudoephedrine—IL2—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000392	0.00278	CbGpPWpGaD
Pseudoephedrine—TNF—Folate Metabolism—CRP—ankylosing spondylitis	0.000387	0.00274	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—CARD9—ankylosing spondylitis	0.000386	0.00273	CbGpPWpGaD
Pseudoephedrine—SLC6A2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.00038	0.00269	CbGpPWpGaD
Pseudoephedrine—TNF—Allograft Rejection—HLA-B—ankylosing spondylitis	0.00038	0.00269	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—IL1R2—ankylosing spondylitis	0.000376	0.00266	CbGpPWpGaD
Pseudoephedrine—SLC6A4—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000375	0.00265	CbGpPWpGaD
Pseudoephedrine—IL2—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000371	0.00263	CbGpPWpGaD
Pseudoephedrine—SLC6A4—Monoamine Transport—TNF—ankylosing spondylitis	0.000362	0.00257	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—ERAP1—ankylosing spondylitis	0.000356	0.00253	CbGpPWpGaD
Pseudoephedrine—TNF—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000352	0.00249	CbGpPWpGaD
Pseudoephedrine—ADRB1—G alpha (s) signalling events—PTGER4—ankylosing spondylitis	0.00035	0.00248	CbGpPWpGaD
Pseudoephedrine—TNF—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	0.000347	0.00246	CbGpPWpGaD
Pseudoephedrine—IL2—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000343	0.00243	CbGpPWpGaD
Pseudoephedrine—ADRB2—G alpha (s) signalling events—PTGER4—ankylosing spondylitis	0.000343	0.00243	CbGpPWpGaD
Pseudoephedrine—SLC6A3—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000336	0.00238	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—CARD9—ankylosing spondylitis	0.000326	0.00231	CbGpPWpGaD
Pseudoephedrine—TNF—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000324	0.00229	CbGpPWpGaD
Pseudoephedrine—SLC6A2—Monoamine Transport—TNF—ankylosing spondylitis	0.000312	0.00221	CbGpPWpGaD
Pseudoephedrine—TNF—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.000308	0.00218	CbGpPWpGaD
Pseudoephedrine—MAOA—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000307	0.00217	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—B3GNT2—ankylosing spondylitis	0.000303	0.00214	CbGpPWpGaD
Pseudoephedrine—IL2—Spinal Cord Injury—TNF—ankylosing spondylitis	0.000296	0.0021	CbGpPWpGaD
Pseudoephedrine—TNF—Spinal Cord Injury—IL1A—ankylosing spondylitis	0.000291	0.00206	CbGpPWpGaD
Pseudoephedrine—SLC6A3—Monoamine Transport—TNF—ankylosing spondylitis	0.000276	0.00196	CbGpPWpGaD
Pseudoephedrine—SLC6A4—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.00027	0.00191	CbGpPWpGaD
Pseudoephedrine—SLC6A4—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000268	0.0019	CbGpPWpGaD
Pseudoephedrine—NFATC1—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000264	0.00187	CbGpPWpGaD
Pseudoephedrine—TNF—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	0.000262	0.00186	CbGpPWpGaD
Pseudoephedrine—NFATC1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000246	0.00174	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—HLA-C—ankylosing spondylitis	0.000242	0.00172	CbGpPWpGaD
Pseudoephedrine—Euphoric mood—Prednisolone—ankylosing spondylitis	0.000233	0.0181	CcSEcCtD
Pseudoephedrine—TNF—Spinal Cord Injury—TLR4—ankylosing spondylitis	0.000233	0.00165	CbGpPWpGaD
Pseudoephedrine—TNF—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000233	0.00165	CbGpPWpGaD
Pseudoephedrine—TNF—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000232	0.00164	CbGpPWpGaD
Pseudoephedrine—Delirium—Prednisone—ankylosing spondylitis	0.00023	0.0178	CcSEcCtD
Pseudoephedrine—IL2—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000229	0.00162	CbGpPWpGaD
Pseudoephedrine—MAOA—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000221	0.00157	CbGpPWpGaD
Pseudoephedrine—MAOA—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.00022	0.00156	CbGpPWpGaD
Pseudoephedrine—TNF—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000219	0.00155	CbGpPWpGaD
Pseudoephedrine—NFATC1—Innate Immune System—CRP—ankylosing spondylitis	0.000217	0.00154	CbGpPWpGaD
Pseudoephedrine—Euphoric mood—Triamcinolone—ankylosing spondylitis	0.000215	0.0166	CcSEcCtD
Pseudoephedrine—Euphoric mood—Methylprednisolone—ankylosing spondylitis	0.000214	0.0166	CcSEcCtD
Pseudoephedrine—NFATC1—Immune System—IL1RN—ankylosing spondylitis	0.00021	0.00149	CbGpPWpGaD
Pseudoephedrine—NFATC1—Innate Immune System—TLR4—ankylosing spondylitis	0.000208	0.00148	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000208	0.00147	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—HLA-C—ankylosing spondylitis	0.000205	0.00145	CbGpPWpGaD
Pseudoephedrine—TNF—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	0.000205	0.00145	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000195	0.00138	CbGpPWpGaD
Pseudoephedrine—Euphoric mood—Betamethasone—ankylosing spondylitis	0.000195	0.0151	CcSEcCtD
Pseudoephedrine—Euphoric mood—Dexamethasone—ankylosing spondylitis	0.000195	0.0151	CcSEcCtD
Pseudoephedrine—ADRB2—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000191	0.00135	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—CD79A—ankylosing spondylitis	0.000185	0.00131	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—IL1RN—ankylosing spondylitis	0.000178	0.00126	CbGpPWpGaD
Pseudoephedrine—Psychotic disorder—Methylprednisolone—ankylosing spondylitis	0.000177	0.0137	CcSEcCtD
Pseudoephedrine—Irritability—Methylprednisolone—ankylosing spondylitis	0.000173	0.0134	CcSEcCtD
Pseudoephedrine—Euphoric mood—Prednisone—ankylosing spondylitis	0.00017	0.0131	CcSEcCtD
Pseudoephedrine—ADRB1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000167	0.00118	CbGpPWpGaD
Pseudoephedrine—ADRB2—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000163	0.00116	CbGpPWpGaD
Pseudoephedrine—Psychotic disorder—Betamethasone—ankylosing spondylitis	0.000161	0.0125	CcSEcCtD
Pseudoephedrine—Psychotic disorder—Dexamethasone—ankylosing spondylitis	0.000161	0.0125	CcSEcCtD
Pseudoephedrine—ADRA1A—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000158	0.00112	CbGpPWpGaD
Pseudoephedrine—Irritability—Betamethasone—ankylosing spondylitis	0.000157	0.0122	CcSEcCtD
Pseudoephedrine—Irritability—Dexamethasone—ankylosing spondylitis	0.000157	0.0122	CcSEcCtD
Pseudoephedrine—IL2—Immune System—CD79A—ankylosing spondylitis	0.000156	0.00111	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—IL1A—ankylosing spondylitis	0.000151	0.00107	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—CD40LG—ankylosing spondylitis	0.000151	0.00107	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000148	0.00105	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000147	0.00104	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000145	0.00103	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—HLA-B—ankylosing spondylitis	0.000143	0.00101	CbGpPWpGaD
Pseudoephedrine—Psychotic disorder—Prednisone—ankylosing spondylitis	0.00014	0.0108	CcSEcCtD
Pseudoephedrine—Bradycardia—Prednisolone—ankylosing spondylitis	0.000139	0.0108	CcSEcCtD
Pseudoephedrine—Irritability—Prednisone—ankylosing spondylitis	0.000137	0.0106	CcSEcCtD
Pseudoephedrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000135	0.000958	CbGpPWpGaD
Pseudoephedrine—Sweating—Methylprednisolone—ankylosing spondylitis	0.000134	0.0104	CcSEcCtD
Pseudoephedrine—NFATC1—Immune System—HLA-A—ankylosing spondylitis	0.000133	0.00094	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.00013	0.000921	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—IL1A—ankylosing spondylitis	0.000128	0.000907	CbGpPWpGaD
Pseudoephedrine—Bradycardia—Triamcinolone—ankylosing spondylitis	0.000128	0.0099	CcSEcCtD
Pseudoephedrine—Bradycardia—Methylprednisolone—ankylosing spondylitis	0.000127	0.00988	CcSEcCtD
Pseudoephedrine—IL2—Immune System—CD40LG—ankylosing spondylitis	0.000127	0.000902	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000127	0.000902	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—CRP—ankylosing spondylitis	0.000127	0.000896	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000126	0.00089	CbGpPWpGaD
Pseudoephedrine—Hallucination—Methylprednisolone—ankylosing spondylitis	0.000125	0.00965	CcSEcCtD
Pseudoephedrine—ADRB2—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000124	0.000882	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000123	0.000871	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—HLA-A—ankylosing spondylitis	0.000122	0.000868	CbGpPWpGaD
Pseudoephedrine—Arrhythmia—Prednisolone—ankylosing spondylitis	0.000122	0.00945	CcSEcCtD
Pseudoephedrine—NFATC1—Immune System—TLR4—ankylosing spondylitis	0.000121	0.000859	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—HLA-B—ankylosing spondylitis	0.000121	0.000858	CbGpPWpGaD
Pseudoephedrine—Bradycardia—Betamethasone—ankylosing spondylitis	0.000116	0.00898	CcSEcCtD
Pseudoephedrine—Bradycardia—Dexamethasone—ankylosing spondylitis	0.000116	0.00898	CcSEcCtD
Pseudoephedrine—Irritability—Methotrexate—ankylosing spondylitis	0.000114	0.00886	CcSEcCtD
Pseudoephedrine—Hallucination—Betamethasone—ankylosing spondylitis	0.000113	0.00878	CcSEcCtD
Pseudoephedrine—Hallucination—Dexamethasone—ankylosing spondylitis	0.000113	0.00878	CcSEcCtD
Pseudoephedrine—IL2—Immune System—HLA-A—ankylosing spondylitis	0.000112	0.000795	CbGpPWpGaD
Pseudoephedrine—Arrhythmia—Triamcinolone—ankylosing spondylitis	0.000112	0.00869	CcSEcCtD
Pseudoephedrine—Arrhythmia—Methylprednisolone—ankylosing spondylitis	0.000112	0.00867	CcSEcCtD
Pseudoephedrine—IL2—Immune System—CRP—ankylosing spondylitis	0.000107	0.000758	CbGpPWpGaD
Pseudoephedrine—Vertigo—Prednisolone—ankylosing spondylitis	0.000107	0.00827	CcSEcCtD
Pseudoephedrine—NFATC1—Signaling Pathways—MMP3—ankylosing spondylitis	0.000103	0.000733	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000103	0.000729	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—TLR4—ankylosing spondylitis	0.000103	0.000727	CbGpPWpGaD
Pseudoephedrine—Hypertension—Prednisolone—ankylosing spondylitis	0.000103	0.00795	CcSEcCtD
Pseudoephedrine—SLC6A4—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.000102	0.000723	CbGpPWpGaD
Pseudoephedrine—Arrhythmia—Dexamethasone—ankylosing spondylitis	0.000102	0.00788	CcSEcCtD
Pseudoephedrine—Arrhythmia—Betamethasone—ankylosing spondylitis	0.000102	0.00788	CcSEcCtD
Pseudoephedrine—Bradycardia—Prednisone—ankylosing spondylitis	0.000101	0.00782	CcSEcCtD
Pseudoephedrine—Hallucination—Prednisone—ankylosing spondylitis	9.86e-05	0.00765	CcSEcCtD
Pseudoephedrine—Vertigo—Triamcinolone—ankylosing spondylitis	9.81e-05	0.00761	CcSEcCtD
Pseudoephedrine—Vertigo—Methylprednisolone—ankylosing spondylitis	9.79e-05	0.00759	CcSEcCtD
Pseudoephedrine—Dysuria—Methotrexate—ankylosing spondylitis	9.68e-05	0.0075	CcSEcCtD
Pseudoephedrine—ADRA2A—GPCR ligand binding—PTGER4—ankylosing spondylitis	9.57e-05	0.000678	CbGpPWpGaD
Pseudoephedrine—Tachycardia—Prednisolone—ankylosing spondylitis	9.46e-05	0.00733	CcSEcCtD
Pseudoephedrine—Hypertension—Triamcinolone—ankylosing spondylitis	9.43e-05	0.00731	CcSEcCtD
Pseudoephedrine—Hypertension—Methylprednisolone—ankylosing spondylitis	9.41e-05	0.00729	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Prednisolone—ankylosing spondylitis	9.37e-05	0.00726	CcSEcCtD
Pseudoephedrine—Anxiety—Methylprednisolone—ankylosing spondylitis	9.25e-05	0.00717	CcSEcCtD
Pseudoephedrine—Confusional state—Methylprednisolone—ankylosing spondylitis	8.97e-05	0.00695	CcSEcCtD
Pseudoephedrine—Vertigo—Dexamethasone—ankylosing spondylitis	8.9e-05	0.0069	CcSEcCtD
Pseudoephedrine—Vertigo—Betamethasone—ankylosing spondylitis	8.9e-05	0.0069	CcSEcCtD
Pseudoephedrine—Arrhythmia—Prednisone—ankylosing spondylitis	8.86e-05	0.00686	CcSEcCtD
Pseudoephedrine—Sweating—Methotrexate—ankylosing spondylitis	8.85e-05	0.00686	CcSEcCtD
Pseudoephedrine—Insomnia—Prednisolone—ankylosing spondylitis	8.77e-05	0.0068	CcSEcCtD
Pseudoephedrine—IL2—Signaling Pathways—MMP3—ankylosing spondylitis	8.75e-05	0.00062	CbGpPWpGaD
Pseudoephedrine—Tachycardia—Triamcinolone—ankylosing spondylitis	8.7e-05	0.00674	CcSEcCtD
Pseudoephedrine—Tachycardia—Methylprednisolone—ankylosing spondylitis	8.68e-05	0.00673	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	8.62e-05	0.00668	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	8.6e-05	0.00666	CcSEcCtD
Pseudoephedrine—Hypertension—Dexamethasone—ankylosing spondylitis	8.56e-05	0.00663	CcSEcCtD
Pseudoephedrine—Hypertension—Betamethasone—ankylosing spondylitis	8.56e-05	0.00663	CcSEcCtD
Pseudoephedrine—Anxiety—Betamethasone—ankylosing spondylitis	8.41e-05	0.00652	CcSEcCtD
Pseudoephedrine—Anxiety—Dexamethasone—ankylosing spondylitis	8.41e-05	0.00652	CcSEcCtD
Pseudoephedrine—MAOA—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	8.36e-05	0.000592	CbGpPWpGaD
Pseudoephedrine—Pain—Prednisolone—ankylosing spondylitis	8.29e-05	0.00642	CcSEcCtD
Pseudoephedrine—Insomnia—Triamcinolone—ankylosing spondylitis	8.06e-05	0.00625	CcSEcCtD
Pseudoephedrine—Insomnia—Methylprednisolone—ankylosing spondylitis	8.04e-05	0.00624	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Prednisolone—ankylosing spondylitis	7.99e-05	0.00619	CcSEcCtD
Pseudoephedrine—Dyspnoea—Triamcinolone—ankylosing spondylitis	7.95e-05	0.00616	CcSEcCtD
Pseudoephedrine—Agitation—Prednisone—ankylosing spondylitis	7.93e-05	0.00615	CcSEcCtD
Pseudoephedrine—Tachycardia—Betamethasone—ankylosing spondylitis	7.89e-05	0.00612	CcSEcCtD
Pseudoephedrine—Tachycardia—Dexamethasone—ankylosing spondylitis	7.89e-05	0.00612	CcSEcCtD
Pseudoephedrine—Dyspepsia—Triamcinolone—ankylosing spondylitis	7.85e-05	0.00608	CcSEcCtD
Pseudoephedrine—Dyspepsia—Methylprednisolone—ankylosing spondylitis	7.83e-05	0.00607	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	7.82e-05	0.00606	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Betamethasone—ankylosing spondylitis	7.82e-05	0.00606	CcSEcCtD
Pseudoephedrine—Vertigo—Prednisone—ankylosing spondylitis	7.75e-05	0.00601	CcSEcCtD
Pseudoephedrine—Anorexia—Dexamethasone—ankylosing spondylitis	7.71e-05	0.00598	CcSEcCtD
Pseudoephedrine—Anorexia—Betamethasone—ankylosing spondylitis	7.71e-05	0.00598	CcSEcCtD
Pseudoephedrine—Pain—Triamcinolone—ankylosing spondylitis	7.62e-05	0.00591	CcSEcCtD
Pseudoephedrine—MAOA—Metabolism—B3GNT2—ankylosing spondylitis	7.57e-05	0.000536	CbGpPWpGaD
Pseudoephedrine—Hypertension—Prednisone—ankylosing spondylitis	7.45e-05	0.00578	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Triamcinolone—ankylosing spondylitis	7.35e-05	0.00569	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	7.33e-05	0.00568	CcSEcCtD
Pseudoephedrine—Anxiety—Prednisone—ankylosing spondylitis	7.32e-05	0.00568	CcSEcCtD
Pseudoephedrine—Insomnia—Dexamethasone—ankylosing spondylitis	7.32e-05	0.00567	CcSEcCtD
Pseudoephedrine—Insomnia—Betamethasone—ankylosing spondylitis	7.32e-05	0.00567	CcSEcCtD
Pseudoephedrine—ADRB1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	7.19e-05	0.000509	CbGpPWpGaD
Pseudoephedrine—Dyspepsia—Dexamethasone—ankylosing spondylitis	7.12e-05	0.00552	CcSEcCtD
Pseudoephedrine—Dyspepsia—Betamethasone—ankylosing spondylitis	7.12e-05	0.00552	CcSEcCtD
Pseudoephedrine—Body temperature increased—Triamcinolone—ankylosing spondylitis	7.05e-05	0.00546	CcSEcCtD
Pseudoephedrine—ADRB2—GPCR downstream signaling—PTGER4—ankylosing spondylitis	7.03e-05	0.000498	CbGpPWpGaD
Pseudoephedrine—Decreased appetite—Dexamethasone—ankylosing spondylitis	7.03e-05	0.00545	CcSEcCtD
Pseudoephedrine—Decreased appetite—Betamethasone—ankylosing spondylitis	7.03e-05	0.00545	CcSEcCtD
Pseudoephedrine—Pain—Dexamethasone—ankylosing spondylitis	6.92e-05	0.00536	CcSEcCtD
Pseudoephedrine—Pain—Betamethasone—ankylosing spondylitis	6.92e-05	0.00536	CcSEcCtD
Pseudoephedrine—Tachycardia—Prednisone—ankylosing spondylitis	6.87e-05	0.00533	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Prednisone—ankylosing spondylitis	6.81e-05	0.00528	CcSEcCtD
Pseudoephedrine—Anorexia—Prednisone—ankylosing spondylitis	6.71e-05	0.0052	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Dexamethasone—ankylosing spondylitis	6.66e-05	0.00517	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Betamethasone—ankylosing spondylitis	6.66e-05	0.00517	CcSEcCtD
Pseudoephedrine—ADRB1—Signaling by GPCR—PTGER4—ankylosing spondylitis	6.53e-05	0.000463	CbGpPWpGaD
Pseudoephedrine—Vertigo—Methotrexate—ankylosing spondylitis	6.48e-05	0.00502	CcSEcCtD
Pseudoephedrine—Dizziness—Prednisolone—ankylosing spondylitis	6.41e-05	0.00497	CcSEcCtD
Pseudoephedrine—Asthenia—Triamcinolone—ankylosing spondylitis	6.4e-05	0.00496	CcSEcCtD
Pseudoephedrine—Body temperature increased—Betamethasone—ankylosing spondylitis	6.39e-05	0.00496	CcSEcCtD
Pseudoephedrine—Body temperature increased—Dexamethasone—ankylosing spondylitis	6.39e-05	0.00496	CcSEcCtD
Pseudoephedrine—ADRB2—Signaling by GPCR—PTGER4—ankylosing spondylitis	6.39e-05	0.000453	CbGpPWpGaD
Pseudoephedrine—Asthenia—Methylprednisolone—ankylosing spondylitis	6.38e-05	0.00495	CcSEcCtD
Pseudoephedrine—Insomnia—Prednisone—ankylosing spondylitis	6.37e-05	0.00494	CcSEcCtD
Pseudoephedrine—Dyspepsia—Prednisone—ankylosing spondylitis	6.2e-05	0.00481	CcSEcCtD
Pseudoephedrine—Chest pain—Methotrexate—ankylosing spondylitis	6.14e-05	0.00476	CcSEcCtD
Pseudoephedrine—Decreased appetite—Prednisone—ankylosing spondylitis	6.12e-05	0.00475	CcSEcCtD
Pseudoephedrine—Rash—Prednisolone—ankylosing spondylitis	6.11e-05	0.00474	CcSEcCtD
Pseudoephedrine—Dermatitis—Prednisolone—ankylosing spondylitis	6.11e-05	0.00473	CcSEcCtD
Pseudoephedrine—Headache—Prednisolone—ankylosing spondylitis	6.07e-05	0.00471	CcSEcCtD
Pseudoephedrine—Confusional state—Methotrexate—ankylosing spondylitis	5.94e-05	0.0046	CcSEcCtD
Pseudoephedrine—Dizziness—Triamcinolone—ankylosing spondylitis	5.89e-05	0.00457	CcSEcCtD
Pseudoephedrine—Dizziness—Methylprednisolone—ankylosing spondylitis	5.88e-05	0.00456	CcSEcCtD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—PTGER4—ankylosing spondylitis	5.82e-05	0.000412	CbGpPWpGaD
Pseudoephedrine—Feeling abnormal—Prednisone—ankylosing spondylitis	5.8e-05	0.0045	CcSEcCtD
Pseudoephedrine—Asthenia—Dexamethasone—ankylosing spondylitis	5.8e-05	0.0045	CcSEcCtD
Pseudoephedrine—Asthenia—Betamethasone—ankylosing spondylitis	5.8e-05	0.0045	CcSEcCtD
Pseudoephedrine—Nausea—Prednisolone—ankylosing spondylitis	5.76e-05	0.00446	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Methotrexate—ankylosing spondylitis	5.69e-05	0.00441	CcSEcCtD
Pseudoephedrine—Vomiting—Triamcinolone—ankylosing spondylitis	5.67e-05	0.00439	CcSEcCtD
Pseudoephedrine—Vomiting—Methylprednisolone—ankylosing spondylitis	5.65e-05	0.00438	CcSEcCtD
Pseudoephedrine—Rash—Triamcinolone—ankylosing spondylitis	5.62e-05	0.00436	CcSEcCtD
Pseudoephedrine—Dermatitis—Triamcinolone—ankylosing spondylitis	5.61e-05	0.00435	CcSEcCtD
Pseudoephedrine—Anorexia—Methotrexate—ankylosing spondylitis	5.61e-05	0.00435	CcSEcCtD
Pseudoephedrine—Rash—Methylprednisolone—ankylosing spondylitis	5.61e-05	0.00435	CcSEcCtD
Pseudoephedrine—Dermatitis—Methylprednisolone—ankylosing spondylitis	5.6e-05	0.00434	CcSEcCtD
Pseudoephedrine—Headache—Triamcinolone—ankylosing spondylitis	5.58e-05	0.00433	CcSEcCtD
Pseudoephedrine—Headache—Methylprednisolone—ankylosing spondylitis	5.57e-05	0.00432	CcSEcCtD
Pseudoephedrine—Body temperature increased—Prednisone—ankylosing spondylitis	5.57e-05	0.00432	CcSEcCtD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—PTGER4—ankylosing spondylitis	5.41e-05	0.000383	CbGpPWpGaD
Pseudoephedrine—Dizziness—Dexamethasone—ankylosing spondylitis	5.35e-05	0.00415	CcSEcCtD
Pseudoephedrine—Dizziness—Betamethasone—ankylosing spondylitis	5.35e-05	0.00415	CcSEcCtD
Pseudoephedrine—Insomnia—Methotrexate—ankylosing spondylitis	5.32e-05	0.00413	CcSEcCtD
Pseudoephedrine—Nausea—Triamcinolone—ankylosing spondylitis	5.29e-05	0.0041	CcSEcCtD
Pseudoephedrine—ADRA1A—Signaling by GPCR—PTGER4—ankylosing spondylitis	5.28e-05	0.000374	CbGpPWpGaD
Pseudoephedrine—Nausea—Methylprednisolone—ankylosing spondylitis	5.28e-05	0.00409	CcSEcCtD
Pseudoephedrine—Dyspnoea—Methotrexate—ankylosing spondylitis	5.25e-05	0.00407	CcSEcCtD
Pseudoephedrine—Dyspepsia—Methotrexate—ankylosing spondylitis	5.18e-05	0.00402	CcSEcCtD
Pseudoephedrine—Vomiting—Betamethasone—ankylosing spondylitis	5.14e-05	0.00399	CcSEcCtD
Pseudoephedrine—Vomiting—Dexamethasone—ankylosing spondylitis	5.14e-05	0.00399	CcSEcCtD
Pseudoephedrine—Decreased appetite—Methotrexate—ankylosing spondylitis	5.12e-05	0.00397	CcSEcCtD
Pseudoephedrine—Rash—Betamethasone—ankylosing spondylitis	5.1e-05	0.00395	CcSEcCtD
Pseudoephedrine—Rash—Dexamethasone—ankylosing spondylitis	5.1e-05	0.00395	CcSEcCtD
Pseudoephedrine—Dermatitis—Betamethasone—ankylosing spondylitis	5.09e-05	0.00395	CcSEcCtD
Pseudoephedrine—Dermatitis—Dexamethasone—ankylosing spondylitis	5.09e-05	0.00395	CcSEcCtD
Pseudoephedrine—Headache—Betamethasone—ankylosing spondylitis	5.07e-05	0.00393	CcSEcCtD
Pseudoephedrine—Headache—Dexamethasone—ankylosing spondylitis	5.07e-05	0.00393	CcSEcCtD
Pseudoephedrine—ADRA2A—Metabolism—B3GNT2—ankylosing spondylitis	5.06e-05	0.000358	CbGpPWpGaD
Pseudoephedrine—Asthenia—Prednisone—ankylosing spondylitis	5.05e-05	0.00392	CcSEcCtD
Pseudoephedrine—Pain—Methotrexate—ankylosing spondylitis	5.03e-05	0.0039	CcSEcCtD
Pseudoephedrine—ADRA2A—Signaling by GPCR—PTGER4—ankylosing spondylitis	4.91e-05	0.000348	CbGpPWpGaD
Pseudoephedrine—Feeling abnormal—Methotrexate—ankylosing spondylitis	4.85e-05	0.00376	CcSEcCtD
Pseudoephedrine—Nausea—Betamethasone—ankylosing spondylitis	4.8e-05	0.00372	CcSEcCtD
Pseudoephedrine—Nausea—Dexamethasone—ankylosing spondylitis	4.8e-05	0.00372	CcSEcCtD
Pseudoephedrine—Dizziness—Prednisone—ankylosing spondylitis	4.66e-05	0.00361	CcSEcCtD
Pseudoephedrine—Body temperature increased—Methotrexate—ankylosing spondylitis	4.65e-05	0.00361	CcSEcCtD
Pseudoephedrine—ADRB1—Signaling by GPCR—MMP3—ankylosing spondylitis	4.65e-05	0.000329	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—MMP3—ankylosing spondylitis	4.55e-05	0.000322	CbGpPWpGaD
Pseudoephedrine—Vomiting—Prednisone—ankylosing spondylitis	4.48e-05	0.00347	CcSEcCtD
Pseudoephedrine—Rash—Prednisone—ankylosing spondylitis	4.44e-05	0.00344	CcSEcCtD
Pseudoephedrine—Dermatitis—Prednisone—ankylosing spondylitis	4.44e-05	0.00344	CcSEcCtD
Pseudoephedrine—Headache—Prednisone—ankylosing spondylitis	4.41e-05	0.00342	CcSEcCtD
Pseudoephedrine—Asthenia—Methotrexate—ankylosing spondylitis	4.22e-05	0.00327	CcSEcCtD
Pseudoephedrine—Nausea—Prednisone—ankylosing spondylitis	4.18e-05	0.00324	CcSEcCtD
Pseudoephedrine—Dizziness—Methotrexate—ankylosing spondylitis	3.89e-05	0.00302	CcSEcCtD
Pseudoephedrine—ADRB1—Signaling Pathways—PTGER4—ankylosing spondylitis	3.86e-05	0.000273	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PTGER4—ankylosing spondylitis	3.77e-05	0.000267	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—MMP3—ankylosing spondylitis	3.76e-05	0.000267	CbGpPWpGaD
Pseudoephedrine—Vomiting—Methotrexate—ankylosing spondylitis	3.74e-05	0.0029	CcSEcCtD
Pseudoephedrine—Rash—Methotrexate—ankylosing spondylitis	3.71e-05	0.00288	CcSEcCtD
Pseudoephedrine—Dermatitis—Methotrexate—ankylosing spondylitis	3.71e-05	0.00287	CcSEcCtD
Pseudoephedrine—Headache—Methotrexate—ankylosing spondylitis	3.69e-05	0.00286	CcSEcCtD
Pseudoephedrine—Nausea—Methotrexate—ankylosing spondylitis	3.5e-05	0.00271	CcSEcCtD
Pseudoephedrine—ADRA2A—Signaling by GPCR—MMP3—ankylosing spondylitis	3.5e-05	0.000248	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—B3GNT2—ankylosing spondylitis	3.3e-05	0.000233	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PTGER4—ankylosing spondylitis	3.12e-05	0.000221	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PTGER4—ankylosing spondylitis	2.9e-05	0.000205	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MMP3—ankylosing spondylitis	2.75e-05	0.000195	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MMP3—ankylosing spondylitis	2.69e-05	0.00019	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MMP3—ankylosing spondylitis	2.22e-05	0.000157	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MMP3—ankylosing spondylitis	2.06e-05	0.000146	CbGpPWpGaD
